Prospects for a group A streptococcal vaccine

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 1, 2005, Pages 11-16

  McMillan, David J ^a   Chhatwal, Gursharan S ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Bioinformatics; Epidemiology; Group A streptococcus; M protein; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; CARBOHYDRATE BINDING PROTEIN; CELL SURFACE PROTEIN; CYSTEINE PROTEINASE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; LIPOTEICHOIC ACID; M PROTEIN; PHOSPHATE BINDING PROTEIN; RECOMBINANT VACCINE; STREPTOCOCCUS VACCINE; SUPEROXIDE DISMUTASE;

ANTIBACTERIAL ACTIVITY; ANTIBODY RESPONSE; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIAL VIRULENCE; DEVELOPING COUNTRY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IMPETIGO; MOUSE STRAIN; NECROTIZING FASCIITIS; NONHUMAN; PHARYNGITIS; PREDICTION; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; TOXIC SHOCK SYNDROME;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CARRIER PROTEINS; HUMANS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 14244251039     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Cunningham MW: Pathogenesis of group A streptococcal infections. Clin Microbiol Rev (2000) 13(3):470-511.
2. Cunningham MW: T cell mimicry in inflammatory heart disease. Mol Immunol (2004) 40(14-15):1121-1127.
3. Veasy LG, Tani LY, Daly JA, Korgenski K, Miner L, Bale J, Kaplan EL, Musser JM, Hill HR: Temporal association of the appearance of mucoid strains of Streptococcus pyogenes with a continuing high incidence of rheumatic fever in Utah. Pediatrics (2004) 113 3 Pt 1):e168-e172.
4. O'Brien KL, Beall B, Barrett NL, Cieslak PR, Reingold A, Farley MM, Danila R, Zell ER, Facklam R, Schwartz B, Schuchat A et al Epidemiology of invasive group A Streptococcus disease in the United States, 1995-1999. Clin Infect Dis (2002) 35 3):268-276.
5. Dale JB: Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments Vaccine (1999) 17(2):193-200.
6. Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, Wasserman SS, Dale JB: Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults: Phase 1 trial. J Am Med Assoc (2004) 292(6):709-715.
7. Hall MA, Stroop SD, Hu MC, Walls MA, Reddish MA, Burt DS, Lowell GH, Dale JB: Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections. Infect Immun (2004) 72(5):2507-2512.
8. Brandt ER, Teh T, Relf WA, Hobb RI, Good MF: Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci. Infect Immun (2000) 68(12):6587-6594.
9. Bruner M, James A, Beall B, Carlone GM, Ades E, Johnson S, Guamer J, Sampson J: Evaluation of synthetic, M type-specific peptides as antigens in a multivalent group A streptococcal vaccine. Vaccine (2003) 21(21-22):2698-2703.
10. Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB: Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun (2002) 70(4):2171-2177.
11. Brandt ER, Sriprakash KS, Hobb RI, Hayman WA, Zang W, Batzloff MR, Jackson DC, Good MF: New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat Med (2000) 6(4):455-459.
12. Shulman ST, Tanz RR, Kabat W, Kabat K, Cederlund E, Patel D, Li Z, Sakota V, Dale JB, Beall B: Group A streptococcal pharyngitis serotype surveillance in North America, 2000-2002. Clin Infect Dis (2004) 39(3):325-332.
13. Kaplan EL, Wotton JT, Johnson DR: Dynamic epidemiology of group A streptococcal serotypes associated with pharyngitis. Lancet (2001) 358(9290):1334-1337.
14. Eriksson BK, Villasenor-Sierra A, Norgren M, Stevens DL: Opsonization of T1M1 group A Streptococcus: Dynamics of antibody production and strain specificity. Clin Infect Dis (2001) 32 2):E24-E30.
15. Pruksakorn S, Currie B, Brandt E, Martin D, Galbraith A, Phornphutkul C, Hunsakunachai S, Manmontri A, Good MF: Towards a vaccine for rheumatic fever: Identification of a conserved target epitope on M protein of group A streptococci. Lancet (1994) 344 8923):639-642.
16. Bessen D, Fischetti VA: Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. J Immunol (1990) 145(4):1251-1256.
17. Horvath A, Olive C, Karpati L, Sun HK, Good M, Toth I: Toward the development of a synthetic group A streptococcal vaccine of high purity and broad protective coverage. J Med Chem (2004) 47(16):4100-4104.
18. Olive C, Clair T, Yarwood P, Good MF: Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine (2002) 20 21-22):2816-2825.
19. Batzloff MR, Hayman WA, Davies MR, Zeng M, Pruksakom S, Brandt ER, Good MF: Protection against group A Streptococcus by immunization with J8-diphtheria toxoid: Contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis (2003) 187(10):1598-1608.
20. Ji Y, Carlson B, Kondagunta A, Cleary PP: Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus. Infect Immun (1997) 65(6):2080-2087.
21. McCormick JK, Tripp TJ, Olmsted SB, Matsuka YV, Gahr PJ, Ohlendorf DH, Schlievert PM: Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome. J Immunol (2000) 165(4 ):2306-2312.
22. Roggiani M, Stoehr JA, Olmsted SB, Matsuka YV, Pillai S, Ohlendorf DH, Schlievert PM: Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome. Infect Immun (2000) 68(9):5011-5017.
23. Kapur V, Maffei JT, Greer RS, Li LL, Adams GJ, Musser JM: Vaccination with streptococcal extracellular cysteine protease (interleukin-1β convertase) protects mice against challenge with heterologous group A streptococci. Microb Pathog (1994) 16 6):443-450.
24. Salvadori LG, Blake MS, McCarty M, Tai JY, Zabriskie JB: Group A Streptococcus-liposome ELISA antibody titers to group A polysaccharide and opsonophagocytic capabilities of the antibodies. J Infect Dis (1995) 171(3):593-600.
25. Shet A, Kaplan EL, Johnson DR, Cleary PP: Immune response to group A streptococcal C5a peptidase in children: Implications for vaccine development. J Infect Dis (2003) 188(6 ):809-817.
26. Schulze K, Medina E, Talay SR, Towers RJ, Chhatwal GS, Guzman CA: Characterization of the domain of fibronectin-binding protein I of Streptococcus pyogenes responsible for elicitation of a protective immune response. Infect Immun (2001) 69(1):622-625.
27. Guzman CA, Talay SR, Molinari G, Medina E, Chhatwal GS: Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein Sfbl J Infect Dis (1999) 179(4):901-906.
28. Schulze K, Medina E, Chhatwal GS, Guzman CA: Stimulation of long-lasting protection against Streptococcus pyogenes after intranasal vaccination with non adjuvanted fibronectin-binding domain of the Sfbl protein. Vaccine (2003) 21(17-18):1958-1964.
29. Kawabata S, Kunitomo E, Terao Y, Nakagawa I, Kikuchi K, Totsuka K, Hamada S: Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect Immun (2001) 69(2):924-930.
30. Proft T, Webb PD, Handley V, Fraser JD: Two novel superantigens found in both group A and group C Streptococcus. Infect Immun (2003) 71(3):1361-1369.
31. Ferretti JJ, McShan WM, Ajdic D, Savic DJ, Savic G, Lyon K, Primeaux C, Sezate S, Suvorov AN, Kenton S, Lai HS et al: Complete genome sequence of an M1 strain of Streptococcus pyogenes Proc Natl Acad Sci USA (2001) 98(8 ):4658-4663.
32. Banks DJ, Porcella SF, Barbian KD, Beres SB, Philips LE, Voyich JM, DeLeo FR, Martin JM, Somerville GA, Musser JM: Progress toward characterization of the group A Streptococcus metagenome: Complete genome sequence of a macrolide-resistant serotype M6 strain. J Infect Dis (2004) 190(4):727-738.
33. Beres SB, Sylva GL, Barbian KD, Lei B, Hoff JS, Mammarella ND, Liu MY, Smoot JC, Porcella SF, Parkins LD, Campbell DS et al: Genome sequence of a serotype M3 strain of group A Streptococcus Phage-encoded toxins, the high-virulence phenotype, and clone emergence. Proc Natl Acad Sci USA (2002) 99 15):10078-10083.
34. Nakagawa I, Kurokawa K, Yamashita A, Nakata M, Tomiyasu Y, Okahashi N, Kawabata S, Yamazaki K, Shiba T, Yasunaga. T, Hayashi H et al: Genome sequence of an M3 strain of Streptococcus pyogenes reveals a large-scale genomic rearrangement in invasive strains and new insights into phage evolution. Genome Res (2003) 13 6A):1042-1055.
35. Smoot JC, Barbian KD, Van Gompel JJ, Smoot LM, Chaussee MS, Sylva GL, Sturdevant DE, Ricklefs SM, Porcella SF, Parkins LD, Beres SB et al: Genome sequence and comparative microarray analysis of serotype M18 group A Streptococcus strains associated with acute rheumatic fever outbreaks. Proc Natl Acad Sci USA (2002) 99 7):4668-4673.
36. Kalia A, Bessen DE: Presence of streptococcal pyrogenic exotoxin A and C genes in human isolates of group G streptococci. FEMS Microbiol Lett (2003) 219(2):291-295.
37. Lei B, Liu M, Chesney GL, Musser JM: Identification of new candidate vaccine antigens made by Streptococcus pyogenes: Purification and characterization of 16 putative extracellular lipoproteins. J Infect Dis (2004) 189(1):79-89.
38. McMillan DJ, Batzloff MR, Browning CL, Davies MR, Good MF, Sriprakash KS, Janulczyk R, Rasmussen M: Identification and assessment of new vaccine candidates for group A streptococcal infections. Vaccine (2004) 22(21-22):2783-2790.
39. Lei B, Smoot LM, Manning HM, Voyich JM, Kala SV, Deleo FR, Reid SD, Musser JM: Identification and characterization of a novel hemeassociated cell surface protein made by Streptococcus pyogenes Infect Immun (2002) 70(8):4494-4500.
40. Reid SD, Green NM, Sylva GL, Voyich JM, Stenseth ET, DeLeo FR, Palzkill T, Low DE Hill HR, Musser JM: Postgenomic analysis of four novel antigens of group A Streptococcus: Growth phasedependent gene transcription and human serologic response. J Bacteriol (2002) 184(22):6316-6324.
41. Dunn LA, McMillan DJ, Batzloff M, Zeng W, Jackson DC, Upcroft JA, Upcroft P, Olive C: Parenteral and mucosal delivery of a novel multiepitope M protein-based group A streptococcal vaccine construct: Investigation of immunogenicity in mice. Vaccine (2002) 20 21-22):2635-2640.
42. Olive C, Batzloff MR, Horvath A, Wong A, Clair T, Yarwood P, Toth I, Good MF: A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect Immun (2002) 70 5):2734-2738.
43. Olive C, Batzloff M, Horvath A, Clair T, Yarwood P, Toth I, Good MF: Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect Immun (2003) 71(5 ):2373-2383.
44. Mannam P, Jones KF, Geller BL: Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun (2004) 72(6):3444-3450.
45. Bolken TC, Franke CA, Jones KF, Bell RH, Swanson RM, King DS, Fischetti VA, Hruby DE: Analysis of factors affecting surface expression and immunogenicity of recombinant proteins expressed by Gram-positive commensal vectors. Infect Immun (2002) 70 5):2487-2491.
46. 2-macroglobulin-binding protein to bacterial virulence in a mouse skin model of group A streptococcal infection. J Infect Dis (2003) 187(11):1694-1703.
47. Yokoyama Y, Harabuchi Y: Intranasal immunization with lipoteichoic acid and cholera toxin evokes specific pharyngeal IgA and systemic IgG responses and inhibits streptococcal adherence to pharyngeal epithelial cells in mice. Int J Pediatr Otorhinolaryngol (2002) 63(3):235-241.
48. Dale JB, Chiang EY, Liu S, Courtney HS, Hasty DL: New protective antigen of group A streptococci. J Clin Invest (1999) 103(9):1261-1268.
49. Dale JB, Chiang EY, Hasty DL, Courtney HS: Antibodies against a synthetic peptide of SagA neutralize the cytolytic activity of streptolysin S from group A streptococci. Infect Immun (2002) 70(4):2166-2170.
50. McMillan DJ, Davies MR, Good MF, Sriprakash KS: Immune response to superoxide dismutase in group A streptococcal infection. FEMS Immunol Med Microbiol (2004) 40(3):249-256.